CASI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CASI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for CASI Pharmaceuticals's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
CASI Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, CASI Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
CASI Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:
For example, CASI Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | -0.46 | / | 114.6694 | * | 114.6694 | |
= | -0.460 |
Current CPI (Dec. 2023) = 114.6694.
CASI Pharmaceuticals Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201403 | -0.500 | 98.600 | -0.581 |
201406 | -0.600 | 98.200 | -0.701 |
201409 | -7.700 | 98.900 | -8.928 |
201412 | -0.200 | 99.000 | -0.232 |
201503 | -0.600 | 99.900 | -0.689 |
201506 | -0.600 | 99.500 | -0.691 |
201509 | -0.500 | 100.500 | -0.570 |
201512 | -0.500 | 100.600 | -0.570 |
201603 | -0.400 | 102.200 | -0.449 |
201606 | -0.800 | 101.400 | -0.905 |
201609 | -0.300 | 102.400 | -0.336 |
201612 | -0.444 | 102.600 | -0.496 |
201703 | -0.300 | 103.200 | -0.333 |
201706 | -0.400 | 103.100 | -0.445 |
201709 | -0.300 | 104.100 | -0.330 |
201712 | -0.800 | 104.500 | -0.878 |
201803 | -0.500 | 105.300 | -0.544 |
201806 | -0.700 | 104.900 | -0.765 |
201809 | -1.000 | 106.600 | -1.076 |
201812 | -1.000 | 106.500 | -1.077 |
201903 | -0.900 | 107.700 | -0.958 |
201906 | -1.600 | 107.700 | -1.704 |
201909 | -1.000 | 109.800 | -1.044 |
201912 | -1.300 | 111.200 | -1.341 |
202003 | -0.900 | 112.300 | -0.919 |
202006 | -0.900 | 110.400 | -0.935 |
202009 | -1.400 | 111.700 | -1.437 |
202012 | -1.170 | 111.500 | -1.203 |
202103 | -1.100 | 112.662 | -1.120 |
202106 | -0.500 | 111.769 | -0.513 |
202109 | -0.730 | 112.215 | -0.746 |
202112 | -0.390 | 113.108 | -0.395 |
202203 | -0.620 | 114.335 | -0.622 |
202206 | -0.560 | 114.558 | -0.561 |
202209 | -0.380 | 115.339 | -0.378 |
202212 | -1.440 | 115.116 | -1.434 |
202303 | -0.450 | 115.116 | -0.448 |
202306 | -0.770 | 114.558 | -0.771 |
202309 | -0.350 | 115.339 | -0.348 |
202312 | -0.460 | 114.669 | -0.460 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
CASI Pharmaceuticals (NAS:CASI) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of CASI Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
James Huang | director | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Wei-wu He | director, 10 percent owner, officer: Chairman and CEO | ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Weihao Xu | officer: Chief Financial Officer | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Larry Zhang | officer: President | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Shrotriya Rajesh C Md | director | 157 TECHNOLOGY DRIVE, IRVINE CA 92618 |
Salisbury Franklin Cary Jr | director | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Yue Alexander Wu | director | C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121 |
Wealth Strategy Holding Ltd | 10 percent owner | LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK |
Alexander A Zukiwski | officer: Chief Medical Officer | 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
George Chi | officer: Chief Financial Officer | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Dapeng Li | 10 percent owner | BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008 |
Idg-accel China Growth Fund Iii L.p. | 10 percent owner | UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000 |
Spectrum Pharmaceuticals Inc | 10 percent owner | 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052 |
Sparkle Byte Ltd | 10 percent owner | P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000 |
Ken Ren | director, officer: CEO and Director | 3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065 |
From GuruFocus
By PRNewswire PRNewswire • 01-20-2022
By PRNewswire PRNewswire • 06-15-2022
By PRNewswire • 07-20-2023
By PRNewswire PRNewswire • 03-04-2022
By PRNewswire PRNewswire • 03-23-2022
By PRNewswire • 08-11-2023
By PRNewswire PRNewswire • 07-13-2022
By PRNewswire PRNewswire • 03-21-2023
By PRNewswire PRNewswire • 05-17-2023
By PRNewswire PRNewswire • 05-26-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.